SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy Pub Date : 2023-01-01 DOI:10.1159/000527010

Joanna Drozd-Sokolowska, Krzysztof Mądry, Joanna Barankiewicz, Katarzyna Kobylińska, Przemysław Biecek, Jagoda Rytel, Ewa Karakulska-Prystupiuk, Kamila Skwierawska, Aleksander Salomon-Perzyński, Tomasz Stokłosa, Grzegorz Władysław Basak

{"title":"SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.","authors":"Joanna Drozd-Sokolowska, Krzysztof Mądry, Joanna Barankiewicz, Katarzyna Kobylińska, Przemysław Biecek, Jagoda Rytel, Ewa Karakulska-Prystupiuk, Kamila Skwierawska, Aleksander Salomon-Perzyński, Tomasz Stokłosa, Grzegorz Władysław Basak","doi":"10.1159/000527010","DOIUrl":null,"url":null,"abstract":"Introduction: Venetoclax combined with azacitidine (AZA-VEN) constitutes an option for the treatment of acute myeloid leukemia. There are, however, no data on the COVID-19 incidence and outcome in patients treated with AZA-VEN.Methods: Patients with acute leukemia treated with AZA-VEN at a single institution were included in this prospective observational study.Results: Thirteen patients were enrolled, 46% with treatment-naïve, and 56% with relapsed/refractory disease. Fifty-four percent of patients were males; the median age was 69 years. Six patients (46%) developed COVID-19 during the observation time. The median time to COVID-19 was 24 days from the initiation of AZA-VEN. The 2-month cumulative incidence of COVID-19 was 46.2%. Two patients (33%) succumbed to COVID-19. The 100-day COVID-19-free survival from AZA-VEN initiation was 61%. The median follow-up time was 4.3 months.Discussion/conclusion: COVID-19 constitutes a frequent complication of AZA-VEN treatment in the era of the COVID-19 pandemic, leading to death in a significant proportion of patients.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":"68 1","pages":"16-22"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000527010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Venetoclax combined with azacitidine (AZA-VEN) constitutes an option for the treatment of acute myeloid leukemia. There are, however, no data on the COVID-19 incidence and outcome in patients treated with AZA-VEN.

Methods: Patients with acute leukemia treated with AZA-VEN at a single institution were included in this prospective observational study.

Results: Thirteen patients were enrolled, 46% with treatment-naïve, and 56% with relapsed/refractory disease. Fifty-four percent of patients were males; the median age was 69 years. Six patients (46%) developed COVID-19 during the observation time. The median time to COVID-19 was 24 days from the initiation of AZA-VEN. The 2-month cumulative incidence of COVID-19 was 46.2%. Two patients (33%) succumbed to COVID-19. The 100-day COVID-19-free survival from AZA-VEN initiation was 61%. The median follow-up time was 4.3 months.

Discussion/conclusion: COVID-19 constitutes a frequent complication of AZA-VEN treatment in the era of the COVID-19 pandemic, leading to death in a significant proportion of patients.

查看原文本刊更多论文

阿扎胞苷和维妥乐治疗急性白血病患者的SARS-CoV-2感染:单一机构治疗的病例系列报告

简介:Venetoclax联合阿扎胞苷(AZA-VEN)是治疗急性髓系白血病的一种选择。然而，没有关于使用AZA-VEN治疗的患者的COVID-19发病率和结果的数据。方法:在单一机构接受AZA-VEN治疗的急性白血病患者纳入这项前瞻性观察研究。结果:纳入13例患者，46%患有treatment-naïve, 56%患有复发/难治性疾病。54%的患者为男性;平均年龄为69岁。6例患者(46%)在观察期间出现COVID-19。从AZA-VEN开始到COVID-19的中位时间为24天。2个月累计发病率为46.2%。2例(33%)死于COVID-19。AZA-VEN启动后100天无covid -19存活率为61%。中位随访时间为4.3个月。讨论/结论:COVID-19是COVID-19大流行时代AZA-VEN治疗的常见并发症，导致相当比例的患者死亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.